Nedd8-activating enzyme inhibitor mln4924 provides synergy with mitomycin C through interactions with ATR, BRCA1/BRCA2, and chromatin dynamics pathways

Molecular Cancer Therapeutics

Volumn 13, Issue 6, 2014, Pages 1625-1635

  Garcia, Khristofer ^a   Blank, Jonathan L ^a   Bouck, David C ^a   Liu, Xiaozhen J ^a   Sappal, Darshan S ^a   Hather, Greg ^a   Cosmopoulos, Katherine ^a,b   Thomas, Michael P ^a,c   Kuranda, Mike ^a   Pickard, Michael D ^a   Liu, Ray ^a   Bandi, Syamala ^a   Smith, Peter G ^a,c   Lightcap, Eric S ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^b AGIOS PHARMACEUTICALS   (United States)

^c EISAI INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATR PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CHECKPOINT KINASE RAD3; CISPLATIN; CYTARABINE; ENZYME INHIBITOR; FIRTECAN; GEMCITABINE; MITOMYCIN; NEDD8 PROTEIN; PEVONEDISTAT; VELIPARIB; ((1S,2S,4R)-4-(4-((1S)-2,3-DIHYDRO-1H-INDEN-1-YLAMINO)-7H-PYRROLO(2,3-D)PYRIMIDIN-7-YL)-2-HYDROXYCYCLOPENTYL)METHYL SULPHAMATE; ATM PROTEIN; ATR PROTEIN, HUMAN; BRCA2 PROTEIN, HUMAN; CHROMATIN; CYCLOPENTANE DERIVATIVE; PYRIMIDINE DERIVATIVE; UBA3 PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL LINE; CELL DEATH; CHROMATIN; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; DNA REPLICATION; DNA STRAND BREAKAGE; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT; ULTRAVIOLET RADIATION; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; DRUG EFFECTS; DRUG SCREENING; GENETICS; METABOLISM; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; ATAXIA TELANGIECTASIA MUTATED PROTEINS; BRCA1 PROTEIN; BRCA2 PROTEIN; CELL LINE, TUMOR; CHROMATIN; CYCLOPENTANES; DNA DAMAGE; DRUG SYNERGISM; HUMANS; MICE; MITOMYCIN; PYRIMIDINES; UBIQUITIN-ACTIVATING ENZYMES; ULTRAVIOLET RAYS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84902667412     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0634     Document Type: Article

References (40)

1. Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 2009;458:732-6.
2. Sarikas A, Hartmann T, Pan ZQ. The cullin protein family. Genome Biol 2011;12:220.
3. Lin JJ, Milhollen MA, Smith PG, Narayanan U, Dutta A. NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. Cancer Res 2010;70:10310-20.
4. Milhollen MA, Narayanan U, Soucy TA, Veiby PO, Smith PG, Amidon B. Inhibition of NEDD8-activating enzyme induces rereplication and apoptosis in human tumor cells consistent with deregulating CDT1 turnover. Cancer Res 2011;71:3042-51.
5. Blank JL, Liu XJ, Cosmopoulos K, Bouck DC, Garcia K, Bernard H, et al. Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. Cancer Res 2013; 73:225-34.
6. Li JM, Jin J. CRL ubiquitin ligases and DNA damage response. Front Oncol 2012;2:29.
7. Hannah J, Zhou P. Regulation of DNA damage response pathways by the cullin-RING ubiquitin ligases. DNA Repair 2009;8:536-43.
8. Hannb R, Dubiel W. COP9 signalosome function in the DDR. FEBS Lett 2011;585:2845-52.
9. Abbas T, Dutta A. CRL4Cdt2: master coordinator of cell-cycle progression and genome stability. Cell Cycle 2011;10:241-9.
10. Kee Y, Kim JM, D'Andrea AD. Regulated degradation of FANCM in the Fanconi anemia pathway during mitosis. Genes Dev 2009;23:555-60.
11. Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage model for cancer development. Science 2008;319:1352-5. (Pubitemid 351354863)
12. Evertts A, Coller HA. Back to the origin: reconsidering replication, transcription, epigenetics, and cell-cycle control. Genes Cancer 2012;3:678-96.
13. Deans AJ, West SC. DNA interstrand crosslink repair and cancer. Nat Rev Cancer 2011;11:467-80.
14. Muniandy PA, Liu J, Majumdar A, Liu ST, Seidman MM. DNA interstrand crosslink repair in mammalian cells: step by step. Crit Rev Biochem Mol Biol 2009;45:23-49.
15. Minto CF, Schnider TW, Short TG, Gregg KM, Gentilini A, Shafer SL. Response surface model for anesthetic drug interactions. Anesthesiology 2000;92:1603-16. (Pubitemid 30412478)
16. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010;70:440-6.
17. Peterson JJ, Novick SJ. Nonlinear blending: a useful general concept for the assessment of combination drug synergy. J Recept Signal Transduct Res 2007;27:125-46. (Pubitemid 47024328)
18. Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 2007;13:2728-37. (Pubitemid 46795129)
19. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase. Nature 2005;434:913-7. (Pubitemid 40559005)
20. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21. (Pubitemid 40559006)
21. Motegi A, Murakawa Y, Takeda S. The vital link between the ubiquitin-proteasome pathway and DNA repair: impact on cancer therapy. Cancer Lett 2009;283:1-9.
22. Loewe S. The problem of synergism and antagonism of combined drugs. Arzneimittelforschung 1953;3:285-90.
23. Shi JQ, Lasky K, Shinde V, Stringer B, Qian MG, Liao D, et al. MLN0905, a small-molecule PLK1 inhibitor, induces antitumor responses in human models of diffuse large B-cell lymphoma. Mol Cancer Ther 2012;11:2045-53.
24. Chen S, Blank JL, Peters T, Liu XJ, Rappoli DM, Pickard MD, et al. Genome-wide siRNA screen for modulators of cell death induced by proteasome inhibitor bortezomib. Cancer Res 2010;70:4318-26.
25. Xu Y, Sun Y, Jiang X, Ayrapetov MK, Moskwa P, Yang S, et al. The p400 ATPase regulates nucleosome stability and chromatin ubiquitination during DNA repair. J Cell Biol 2010;191:31-43.
26. Courilleau C, Chailleux C, Jauneau A, Grimal F, Briois S, Boutet-Robinet E, et al. The chromatin remodeler p400 ATPase facilitates Rad51-mediated repair of DNA double-strand breaks. J Cell Biol 2012;199:1067-81.
27. Sørensen CS, Hansen LT, Dziegielewski J, Syljuåsen RG, Lundin C, Bartek J, et al. The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat Cell Biol 2005;7:195-201. (Pubitemid 40268135)
28. Bahassi EM, Ovesen JL, Riesenberg AL, Bernstein WZ, Hasty PE, Stambrook PJ. The checkpoint kinases Chk1 and Chk2 regulate the functional associations between hBRCA2 and Rad51 in response to DNA damage. Oncogene 2008;27:3977-85. (Pubitemid 351913634)
29. Pathania S, Nguyen J, Hill SJ, Scully R, Adelmant GO, Marto JA, et al. BRCA1 is required for postreplication repair after UV-induced DNA damage. Mol Cell 2011;44:235-51.
30. Saxena S, Dutta A. Geminin-Cdt1 balance is critical for genetic stability. Mutat Res 2005;569:111-21. (Pubitemid 39643261)
31. McKenna DJ, Gallus M, McKeown SR, Downes CS, McKelvey-Martin VJ. Modi fication of the alkaline Comet assay to allow simultaneous evaluation of mitomycin C-induced DNA cross-link damage and repair of speci fic DNA sequences in RT4 cells. DNA Repair 2003;2:879-90. (Pubitemid 37297452)
32. Groisman R, Kuraoka I, Chevallier O, Gaye N, Magnaldo T, Tanaka K, et al. CSA-dependent degradation of CSB by the ubiquitin-proteasome pathway establishes a link between complementation factors of the Cockayne syndrome. Genes Dev 2006;20:1429-34. (Pubitemid 43830649)
33. Schlacher K, Wu H, Jasin M. A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51-BRCA1/2. Cancer Cell 2012;22:106-16.
34. Ying S, Hamdy FC, Helleday T. Mre11-dependent degradation of stalled DNA replication forks is prevented by BRCA2 and PARP1. Cancer Res 2012;72:2814-21.
35. Schlacher K, Christ N, Siaud N, Egashira A, Wu H, Jasin M. Doublestrand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11. Cell 2011;145:529-42.
36. Hashimoto Y, Ray Chaudhuri A, Lopes M, Costanzo V. Rad51 protects nascent DNA from Mre11-dependent degradation and promotes continuous DNA synthesis. Nat Struct Mol Biol 2010;17:1305-11.
37. Davidson IF, Li A, Blow JJ. Deregulated replication licensing causes DNA fragmentation consistent with head-to-tail fork collision. Mol Cell 2006;24:433-43. (Pubitemid 44647903)
38. Ma T, Chen Y, Zhang F, Yang CY, Wang S, Yu X. RNF111-dependent neddylation activates DNA damage-induced ubiquitination. Mol Cell 2013;49:897-907.
39. Kee Y, Huang M, Chang S, Moreau LA, Park E, Smith PG, et al. Inhibition of the Nedd8 system sensitizes cells to DNA interstrand cross-linking agents. Mol Cancer Res 2012;10:369-77.
40. Jazaeri AA, Shibata E, Park J, Bryant JL, Conaway MR, Modesitt SC, et al. Overcoming platinum resistance in preclinical models of ovarian cancer using the neddylation inhibitor MLN4924. Mol Cancer Ther 2013;12:1958-67.